Johns Hopkins interferon inducer Ampligen
Executive Summary
FDA recently gave go-ahead to shipment of Ampligen for Far East hepatitis/hepatoma clinicals. U.S. Phase II cancer trials are currently underway at Hahnemann University in Philadelphia ("The Pink Sheet" May 21, T&G-3), and more recently at M.D. Anderson in Houston